Patents by Inventor Peter S. Lu
Peter S. Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9629892Abstract: The invention provides methods of treatment or prophylaxis of damaging effects of penetrative injury to the brain or other part of the central nervous system. The methods are based in part on results in a rodent model of penetrative ballistic injury showing that an inhibitor of PDF-95 NMDAR interaction is effective in inhibiting neurological deficits resulting from such injury. The methods are useful for treating subjects having or at risk of penetrative brain injury, including subjects who have been shot in the head or at risk of such injury (e.g., military or law enforcement personnel).Type: GrantFiled: August 12, 2011Date of Patent: April 25, 2017Assignee: NoNO Inc.Inventors: Michael Tymianski, Peter S. Lu, Jonathan David Garman
-
Patent number: 9611315Abstract: The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to E6 proteins from at least three oncogenic strains of HPV. In general, the antibodies bind to amino acids motifs that are conserved between the E6 proteins of different HPV strains, particularly HPV strains 16 and 18. The subject antibodies may be used to detect HPV E6 protein in a sample, and, accordingly, the antibodies find use in a variety of diagnostic applications, including methods of diagnosing cancer. Kits for performing the subject methods and containing the subject antibodies are also provided.Type: GrantFiled: June 20, 2014Date of Patent: April 4, 2017Assignee: Arbor Vita CorporationInventors: Peter S. Lu, Jonathan David Garman, Michael P. Belmares, Chamorro Somoza Diaz-Sarmiento, Johannes Schweizer
-
Patent number: 9365620Abstract: The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS.Type: GrantFiled: May 9, 2014Date of Patent: June 14, 2016Assignee: NoNO Inc.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Patent number: 9061070Abstract: The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases.Type: GrantFiled: September 14, 2012Date of Patent: June 23, 2015Assignee: NoNO, Inc.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Publication number: 20150093742Abstract: The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to E6 proteins from at least three oncogenic strains of HPV. In general, the antibodies bind to amino acids motifs that are conserved between the E6 proteins of different HPV strains, particularly HPV strains 16 and 18. The subject antibodies may be used to detect HPV E6 protein in a sample, and, accordingly, the antibodies find use in a variety of diagnostic applications, including methods of diagnosing cancer. Kits for performing the subject methods and containing the subject antibodies are also provided.Type: ApplicationFiled: June 20, 2014Publication date: April 2, 2015Inventors: Peter S. Lu, Jonathan David Garman, Michael P. Belmares, Chamorro Somoza Diaz-Sarmiento, Johannes Schweizer
-
Publication number: 20150018283Abstract: The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS.Type: ApplicationFiled: May 9, 2014Publication date: January 15, 2015Applicant: NoNO NC.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Patent number: 8748387Abstract: The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS.Type: GrantFiled: November 13, 2012Date of Patent: June 10, 2014Assignee: NoNO Inc.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Patent number: 8633160Abstract: The present invention relates to compositions for use in the modulation of PDZ domain interactions with cognate ligands. Methods of assessing and characterizing PDZ domain interactions from various polypeptides also are provided.Type: GrantFiled: July 3, 2008Date of Patent: January 21, 2014Assignee: Nono Inc.Inventors: Michael P. Belmares, Kenneth A. Mendoza, Peter S. Lu, David Garman, Michael Tymianski
-
Publication number: 20130266968Abstract: The present application describes methods for detecting influenza A and/or influenza B and/or distinguishing between pathogenic and seasonal influenza A subtypes. Many of these preferred formats employ pan-specific antibodies (i.e., that react with all or at least multiple strains within an influenza type) to detect presence of influenza A and/or influenza B and PDZ domains in combination with panspecific antibodies to influenza A to distinguish pathogenic and seasonal influenza A subtypes.Type: ApplicationFiled: August 29, 2012Publication date: October 10, 2013Applicant: Arbor Vita CorporationInventors: Peter S. Lu, Michael Belmares
-
Publication number: 20130267470Abstract: The invention provides methods of treatment or prophylaxis of damaging effects of penetrative injury to the brain or other part of the central nervous system. The methods are based in part on results in a rodent model of penetrative ballistic injury showing that an inhibitor of PDF-95 NMDAR interaction is effective in inhibiting neurological deficits resulting from such injury. The methods are useful for treating subjects having or at risk of penetrative brain injury, including subjects who have been shot in the head or at risk of such injury (e.g., military or law enforcement personnel).Type: ApplicationFiled: August 12, 2011Publication date: October 10, 2013Applicant: NoNO Inc.Inventors: Michael Tymianski, Peter S. Lu, Jonathan David Garman
-
Patent number: 8536129Abstract: The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.Type: GrantFiled: July 19, 2011Date of Patent: September 17, 2013Assignee: NoNO Inc.Inventors: Andrew Tasker, Tracy Doucette, Michael Tymianski, Kenneth Mendoza, Michael P. Belmares, David Garman, Peter S. Lu
-
Publication number: 20130172230Abstract: The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases.Type: ApplicationFiled: September 14, 2012Publication date: July 4, 2013Applicants: Arbor Vita Corporation, NoNo Inc.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Publication number: 20130017572Abstract: Synthetic DNA molecules encoding various HPV proteins are provided. The codons of the synthetic molecules are designed so as to use the codons that preferentially increase expression of the polypeptide in the host cell, which in preferred embodiments is a human cell. The codons are modified in order to minimize, decrease or eliminate cellular destruction of the polypeptide construct.Type: ApplicationFiled: April 30, 2010Publication date: January 17, 2013Inventors: Peter S. Lu, Johannes Schweizer, Chamorro Somoza Diaz-Sarmiento
-
Patent number: 8324168Abstract: The invention provides agents useful for treating pain. An exemplary agent comprises or consists of the a portion of a retroviral Tat protein. One such agent is the peptide Tat-NR2B9c. This peptide has previously been described as an agent for inhibiting damaging effects of stroke and similar conditions via inhibition of PSD95 interactions with NMDA receptors and/or NOS. The present application provides data showing that the Tat-NR2B9c peptides is effective in alleviation of pain. The alleviation of pain can be obtained at a dose of the peptide below the dose required to inhibit PSD-95 interactions with NMDAR or NOS.Type: GrantFiled: September 3, 2009Date of Patent: December 4, 2012Assignee: NoNO Inc.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Patent number: 8288345Abstract: The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases.Type: GrantFiled: February 29, 2008Date of Patent: October 16, 2012Assignee: Nono, Inc.Inventors: Michael P. Belmares, Jonathan David Garman, Peter S. Lu, Michael W. Salter, Michael Tymianski
-
Publication number: 20120258890Abstract: The present application describes methods for assessing influenza infection, including prognosis. An assay that determines the amount of the NS1 and NP proteins of influenza virus shows enhanced sensitivity and reliability compared to either antigen alone. Many formats employ pan-specific antibodies (i.e., that react with all or at least with multiple strains within an influenza type).Type: ApplicationFiled: April 4, 2012Publication date: October 11, 2012Applicant: ARBOR VITA CORPORATIONInventors: PETER S. LU, MICHAEL P. BELMARES, CAROL TAN, LINDA MCALLISTER
-
Patent number: 8163474Abstract: The present application describes methods for assessing influenza infection, including prognosis. An assay that determines the amount of the NS1 and NP proteins of influenza virus shows enhanced sensitivity and reliability compared to either antigen alone. Many formats employ pan-specific antibodies (i.e., that react with all or at least with multiple strains within an influenza type).Type: GrantFiled: March 16, 2009Date of Patent: April 24, 2012Assignee: Arbor Vita CorporationInventors: Peter S. Lu, Michael P. Belmares, Carol Tan, Linda McAllister
-
Publication number: 20120093873Abstract: The invention provides reagents and methods for inhibiting or enhancing interactions between proteins in hematopoietic cells and other cells involved in the mediation of an immune response. Reagents and methods provided are useful for treatment of a variety of diseases and conditions mediated by immune system cells.Type: ApplicationFiled: September 24, 2010Publication date: April 19, 2012Applicant: ARBOR VITA CORPORATIONInventors: PETER S. LU, JOSHUA D. RABINOWITZ, JOHANNES SCHWEIZER
-
Publication number: 20120083449Abstract: The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.Type: ApplicationFiled: July 19, 2011Publication date: April 5, 2012Applicants: Arbor Vita Corporation, NoNO Inc.Inventors: Andrew Tasker, Tracy Doucette, Michael Tymianski, Kenneth Mendoza, Michael P. Belmares, David Garman, Peter S. Lu
-
Publication number: 20120052484Abstract: The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.Type: ApplicationFiled: August 18, 2011Publication date: March 1, 2012Inventors: Peter S. Lu, Johannes Schweizer, Chamorro Somoza Diaz-Sarmiento, Michael P. Belmares